| Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers M Li, D Spakowicz, J Burkart, S Patel, M Husain, K He, EM Bertino, ... Journal of cancer research and clinical oncology 145, 2541-2546, 2019 | 94 | 2019 |
| Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications D Spakowicz, R Hoyd, M Muniak, M Husain, JS Bassett, L Wang, ... BMC cancer 20, 1-13, 2020 | 52 | 2020 |
| Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC MV Negrao, HA Araujo, G Lamberti, AJ Cooper, NS Akhave, T Zhou, ... Cancer discovery 13 (7), 1556-1571, 2023 | 43 | 2023 |
| Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer AC Johns, L Wei, M Grogan, R Hoyd, JFP Bridges, SH Patel, M Li, ... Journal of geriatric oncology 12 (5), 813-819, 2021 | 23 | 2021 |
| Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival TC Haddad, S Zhao, M Li, SH Patel, A Johns, M Grogan, G Lopez, A Miah, ... Cancer Immunology, Immunotherapy, 1-9, 2022 | 16 | 2022 |
| Serum albumin: early prognostic marker of benefit for immune checkpoint inhibitor monotherapy but not chemoimmunotherapy Y Guo, L Wei, SH Patel, G Lopez, M Grogan, M Li, T Haddad, A Johns, ... Clinical lung cancer 23 (4), 345-355, 2022 | 15 | 2022 |
| Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer M Li, D Spakowicz, S Zhao, SH Patel, A Johns, M Grogan, A Miah, ... Cancer Immunology, Immunotherapy 69, 2403-2408, 2020 | 13 | 2020 |
| Safety and activity of immune checkpoint inhibitors in people living with HIV and cancer: A real-world report from the cancer therapy using checkpoint inhibitors in people … T El Zarif, AH Nassar, E Adib, BG Fitzgerald, J Huang, TH Mouhieddine, ... Journal of Clinical Oncology 41 (21), 3712-3723, 2023 | 12 | 2023 |
| A multicenter study assessing survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitor therapy with and without cytoreductive nephrectomy EE Gross, M Li, M Yin, D Orcutt, D Hussey, E Trott, SK Holt, ER Dwyer, ... Urologic Oncology: Seminars and Original Investigations 41 (1), 51. e25-51. e31, 2023 | 10 | 2023 |
| Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma Y Yang, SP Psutka, AB Parikh, M Li, K Collier, A Miah, SV Mori, M Hinkley, ... Cancer Medicine 11 (16), 3106-3114, 2022 | 10 | 2022 |
| Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival A Miah, G Tinoco, S Zhao, L Wei, A Johns, S Patel, M Li, M Grogan, ... Journal of Cancer Research and Clinical Oncology 149 (5), 2235-2242, 2023 | 8 | 2023 |
| Comparative assessment of manual chart review and ICD claims data in evaluating immunotherapy-related adverse events A Nashed, S Zhang, CW Chiang, M Zitu, GA Otterson, CJ Presley, ... Cancer Immunology, Immunotherapy, 1-9, 2021 | 8 | 2021 |
| Proton pump inhibitor use (PPI) in patients treated with immune checkpoint inhibitors (ICI) for advanced cancer: Survival and prior therapy. M Husain, M Xu, S Patel, A Johns, M Grogan, M Li, G Lopez, A Miah, ... Journal of Clinical Oncology 39 (15_suppl), 2633-2633, 2021 | 8 | 2021 |
| Association of medical comorbidities and cardiovascular disease with toxicity and survival in patients receiving checkpoint inhibitor immunotherapy. A Johns, L Wei, M Grogan, S Patel, M Li, M Husain, KL Kendra, ... Journal of Clinical Oncology 38 (15_suppl), 7039-7039, 2020 | 7 | 2020 |
| VBLC: visibility boosting and logit-constraint learning for domain adaptive semantic segmentation under adverse conditions M Li, B Xie, S Li, CH Liu, X Cheng Proceedings of the AAAI Conference on Artificial Intelligence 37 (7), 8605-8613, 2023 | 6 | 2023 |
| Salvage nivolumab and ipilimumab after prior anti‐PD‐1/PD‐L1 therapy in metastatic renal cell carcinoma: A meta‐analysis Y Yang, SV Mori, M Li, M Hinkley, AB Parikh, KA Collier, A Miah, M Yin Cancer Medicine 11 (7), 1669-1677, 2022 | 5 | 2022 |
| Mean platelet volume, thrombocytosis, and survival in non-small cell lung cancer patients treated with first-line pembrolizumab alone or with chemotherapy M Li, S Zhao, G Lopez, A Secor, P Das, N Surya, M Grogan, S Patel, ... Cancer Immunology, Immunotherapy 72 (7), 2067-2074, 2023 | 3 | 2023 |
| Association between pre-treatment chest imaging and pulmonary function abnormalities and immune checkpoint inhibitor pneumonitis A Wong, M Riley, S Zhao, JG Wang, V Esguerra, M Li, G Lopez, ... Cancer Immunology, Immunotherapy 72 (6), 1727-1735, 2023 | 3 | 2023 |
| Refractory dermatitis contributed by pityriasis versicolor: a case report M Li, N Spaccarelli, K Kendra, RC Wu, C Verschraegen Journal of Medical Case Reports 15, 1-5, 2021 | 3 | 2021 |
| Risk factors for immune checkpoint inhibitor immunotherapy toxicity among older adults with cancer AC Johns, M Yang, L Wei, M Grogan, D Spakowicz, SH Patel, M Li, ... The Oncologist 28 (8), e625-e632, 2023 | 2 | 2023 |
